Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer
Quick Facts
- Publication title: Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer
- Journal: Oncol Res
- Year: 2025
- DOI: 10.32604/or.2024.050431
- PMID/PMCID: 39866224; PMC11753999
Research overview
In this study, we screened out miR-224-3p related to GC progression and LNM in a vascular endothelial growth Factor C (VEGFC)-independent manner. Our discovery of the exo-miR-224-3p/GSK3B/β-catenin/PROX1 axis may provide a new direction for the clinical treatment of GC.
Key findings
In this study, we screened out miR-224-3p related to GC progression and LNM in a vascular endothelial growth Factor C (VEGFC)-independent manner.
We found that exo-miR-224-3p derived from GC cells could enter human lymphatic endothelial cells (HLECs) and promote the tube formation and migration of HLECs.
In addition, it was revealed that miR-224-3p could bind to the 3'UTR region of GSK3B mRNA.
Then, we proved that inhibiting the expression of GSK3B could suppress the phosphorylation of β-catenin and promote the transcription of PROX1, thus leading to tumor lymphangiogenesis.
Study design
We used sequencing analysis of collected serum to screen out exo-miRNA related to LNM in GC.
ELISA, qRT-PCR, Western Blot, RNA pull-down assay, Transwell assay, animal experiments, and other experiments were used to verify the results.
Echo Biotech Role
Echo Biotech contributed EV characterization.
Related platforms: Exoomics®
Related services and capabilities: EV Basic Characterization (TEM/NTA/WB)
References
Original publication: Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer Oncology research. 2025. DOI: 10.32604/or.2024.050431. PMID/PMCID: 39866224; PMC11753999.